New Drug Offers Hope for Children with Dravet Syndrome, Reducing Seizures by Up to 91%

A groundbreaking new treatment, zorevunersen, is showing remarkable promise for children battling Dravet syndrome, a severe and often debilitating form of epilepsy. Clinical trials have demonstrated a significant reduction in seizure frequency – up to 91% – alongside improvements in quality of life for young patients.

Understanding Dravet Syndrome

Dravet syndrome is a rare and devastating genetic condition that typically begins in the first year of life. It’s characterized by frequent, hard-to-control seizures and can lead to long-term neurodevelopmental impairment, feeding difficulties, movement problems, and an increased risk of premature death . The condition was first described by French pediatric neurologist Charlotte Dravet in 1978 .

How Zorevunersen Works

Zorevunersen, developed by Stoke Therapeutics in collaboration with Biogen, targets the underlying genetic cause of Dravet syndrome. Most individuals with Dravet syndrome have a faulty SCN1A gene, where one copy doesn’t produce enough protein for proper nerve cell function . This new medication works by increasing the levels of protein produced by the healthy SCN1A gene, aiming to restore proper nerve cell function .

Clinical Trial Results

An international clinical trial, led by University College London (UCL) and Great Ormond Street Hospital (GOSH), involved 81 children with Dravet syndrome aged between two and 18 years . Prior to treatment, these children experienced an average of 17 seizures per month .

Participants received zorevunersen via lumbar puncture, with some receiving a single dose and others receiving additional doses over a six-month period. An extension study involving 75 children showed that those receiving a 70mg dose experienced a 59% to 91% reduction in seizure frequency during the first 20 months compared to their baseline seizure rates .

Importantly, the study also indicated potential benefits for cognitive and behavioral impacts associated with Dravet syndrome, with children showing improvements in quality of life over a three-year period . Most reported side effects were mild .

Expert Perspective

Professor Helen Cross, of the Institute of Child Health at UCL and Honorary Consultant at GOSH, emphasized the significance of this treatment, stating, “I often see patients with refractory genetic epilepsy, the effects of which extend far beyond the seizures themselves, which is heartbreaking when treatment options are limited. This new treatment could help children with Dravet syndrome live healthier, happier lives.”

Looking Ahead

The promising results from these trials have paved the way for a larger Phase 3 trial to further evaluate the efficacy and safety of zorevunersen. This new treatment offers a beacon of hope for children and families affected by Dravet syndrome, potentially transforming their lives and offering a brighter future.